nodes	percent_of_prediction	percent_of_DWPC	metapath
Pseudoephedrine—TNF—atherosclerosis	0.535	1	CbGaD
Pseudoephedrine—CYP2D6—Niacin—atherosclerosis	0.0321	0.3	CbGbCtD
Pseudoephedrine—CYP2D6—Simvastatin—atherosclerosis	0.0254	0.237	CbGbCtD
Pseudoephedrine—CYP2D6—Pravastatin—atherosclerosis	0.0249	0.232	CbGbCtD
Pseudoephedrine—CYP2D6—Lovastatin—atherosclerosis	0.0249	0.232	CbGbCtD
Pseudoephedrine—IL2—blood vessel—atherosclerosis	0.00776	0.21	CbGeAlD
Pseudoephedrine—NFATC1—connective tissue—atherosclerosis	0.00435	0.118	CbGeAlD
Pseudoephedrine—IL2—connective tissue—atherosclerosis	0.00398	0.108	CbGeAlD
Pseudoephedrine—NFATC1—cardiovascular system—atherosclerosis	0.00379	0.102	CbGeAlD
Pseudoephedrine—IL2—cardiovascular system—atherosclerosis	0.00346	0.0937	CbGeAlD
Pseudoephedrine—NFATC1—adipose tissue—atherosclerosis	0.00334	0.0903	CbGeAlD
Pseudoephedrine—IL2—liver—atherosclerosis	0.00214	0.0579	CbGeAlD
Pseudoephedrine—Urinary retention—Niacin—atherosclerosis	0.0013	0.0157	CcSEcCtD
Pseudoephedrine—Arrhythmia—Rosuvastatin—atherosclerosis	0.00116	0.014	CcSEcCtD
Pseudoephedrine—Angina pectoris—Niacin—atherosclerosis	0.00115	0.0139	CcSEcCtD
Pseudoephedrine—Angina pectoris—Pravastatin—atherosclerosis	0.00113	0.0137	CcSEcCtD
Pseudoephedrine—Dysuria—Pravastatin—atherosclerosis	0.00109	0.0131	CcSEcCtD
Pseudoephedrine—Sweating—Niacin—atherosclerosis	0.00101	0.0122	CcSEcCtD
Pseudoephedrine—ADRB1—connective tissue—atherosclerosis	0.000998	0.027	CbGeAlD
Pseudoephedrine—Confusional state—Rosuvastatin—atherosclerosis	0.00093	0.0112	CcSEcCtD
Pseudoephedrine—Muscle spasms—Lovastatin—atherosclerosis	0.000921	0.0111	CcSEcCtD
Pseudoephedrine—Muscle spasms—Ezetimibe—atherosclerosis	0.000904	0.0109	CcSEcCtD
Pseudoephedrine—Tremor—Lovastatin—atherosclerosis	0.000898	0.0109	CcSEcCtD
Pseudoephedrine—ADRB1—cardiovascular system—atherosclerosis	0.000868	0.0235	CbGeAlD
Pseudoephedrine—Muscle spasms—Simvastatin—atherosclerosis	0.000862	0.0104	CcSEcCtD
Pseudoephedrine—Vertigo—Lovastatin—atherosclerosis	0.000861	0.0104	CcSEcCtD
Pseudoephedrine—Arrhythmia—Niacin—atherosclerosis	0.000845	0.0102	CcSEcCtD
Pseudoephedrine—Tremor—Simvastatin—atherosclerosis	0.00084	0.0102	CcSEcCtD
Pseudoephedrine—Insomnia—Rosuvastatin—atherosclerosis	0.000835	0.0101	CcSEcCtD
Pseudoephedrine—Arrhythmia—Pravastatin—atherosclerosis	0.000831	0.0101	CcSEcCtD
Pseudoephedrine—Palpitations—Ezetimibe—atherosclerosis	0.000831	0.01	CcSEcCtD
Pseudoephedrine—Chest pain—Lovastatin—atherosclerosis	0.000816	0.00986	CcSEcCtD
Pseudoephedrine—Anxiety—Lovastatin—atherosclerosis	0.000813	0.00983	CcSEcCtD
Pseudoephedrine—Dyspepsia—Rosuvastatin—atherosclerosis	0.000812	0.00982	CcSEcCtD
Pseudoephedrine—Hypertension—Ezetimibe—atherosclerosis	0.000811	0.00981	CcSEcCtD
Pseudoephedrine—Tension—Niacin—atherosclerosis	0.000808	0.00976	CcSEcCtD
Pseudoephedrine—Vertigo—Simvastatin—atherosclerosis	0.000805	0.00973	CcSEcCtD
Pseudoephedrine—Chest pain—Ezetimibe—atherosclerosis	0.0008	0.00967	CcSEcCtD
Pseudoephedrine—Nervousness—Niacin—atherosclerosis	0.000799	0.00966	CcSEcCtD
Pseudoephedrine—Tension—Pravastatin—atherosclerosis	0.000795	0.00961	CcSEcCtD
Pseudoephedrine—Muscle spasms—Niacin—atherosclerosis	0.000791	0.00956	CcSEcCtD
Pseudoephedrine—Pain—Rosuvastatin—atherosclerosis	0.000789	0.00954	CcSEcCtD
Pseudoephedrine—Confusional state—Lovastatin—atherosclerosis	0.000788	0.00953	CcSEcCtD
Pseudoephedrine—Nervousness—Pravastatin—atherosclerosis	0.000787	0.00951	CcSEcCtD
Pseudoephedrine—MAOA—connective tissue—atherosclerosis	0.000782	0.0211	CbGeAlD
Pseudoephedrine—Muscle spasms—Pravastatin—atherosclerosis	0.000779	0.00942	CcSEcCtD
Pseudoephedrine—Confusional state—Ezetimibe—atherosclerosis	0.000773	0.00935	CcSEcCtD
Pseudoephedrine—ADRB1—adipose tissue—atherosclerosis	0.000765	0.0207	CbGeAlD
Pseudoephedrine—Chest pain—Simvastatin—atherosclerosis	0.000763	0.00922	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.00076	0.00919	CcSEcCtD
Pseudoephedrine—Anxiety—Simvastatin—atherosclerosis	0.00076	0.00919	CcSEcCtD
Pseudoephedrine—Tremor—Pravastatin—atherosclerosis	0.000759	0.00918	CcSEcCtD
Pseudoephedrine—Anorexia—Lovastatin—atherosclerosis	0.000745	0.00901	CcSEcCtD
Pseudoephedrine—Vertigo—Niacin—atherosclerosis	0.000739	0.00894	CcSEcCtD
Pseudoephedrine—Confusional state—Simvastatin—atherosclerosis	0.000738	0.00892	CcSEcCtD
Pseudoephedrine—Vertigo—Pravastatin—atherosclerosis	0.000728	0.0088	CcSEcCtD
Pseudoephedrine—Palpitations—Niacin—atherosclerosis	0.000727	0.00879	CcSEcCtD
Pseudoephedrine—Insomnia—Lovastatin—atherosclerosis	0.000707	0.00855	CcSEcCtD
Pseudoephedrine—Hypertension—Pravastatin—atherosclerosis	0.0007	0.00846	CcSEcCtD
Pseudoephedrine—Anorexia—Simvastatin—atherosclerosis	0.000697	0.00843	CcSEcCtD
Pseudoephedrine—Dyspnoea—Lovastatin—atherosclerosis	0.000697	0.00843	CcSEcCtD
Pseudoephedrine—Insomnia—Ezetimibe—atherosclerosis	0.000694	0.00839	CcSEcCtD
Pseudoephedrine—Chest pain—Pravastatin—atherosclerosis	0.00069	0.00834	CcSEcCtD
Pseudoephedrine—Dyspepsia—Lovastatin—atherosclerosis	0.000688	0.00832	CcSEcCtD
Pseudoephedrine—Anxiety—Pravastatin—atherosclerosis	0.000687	0.00831	CcSEcCtD
Pseudoephedrine—ADRA1A—cardiovascular system—atherosclerosis	0.000686	0.0186	CbGeAlD
Pseudoephedrine—Dyspnoea—Ezetimibe—atherosclerosis	0.000684	0.00827	CcSEcCtD
Pseudoephedrine—MAOA—cardiovascular system—atherosclerosis	0.00068	0.0184	CbGeAlD
Pseudoephedrine—Decreased appetite—Lovastatin—atherosclerosis	0.00068	0.00822	CcSEcCtD
Pseudoephedrine—Dyspepsia—Ezetimibe—atherosclerosis	0.000675	0.00816	CcSEcCtD
Pseudoephedrine—Pain—Lovastatin—atherosclerosis	0.000669	0.00808	CcSEcCtD
Pseudoephedrine—Confusional state—Pravastatin—atherosclerosis	0.000667	0.00806	CcSEcCtD
Pseudoephedrine—Decreased appetite—Ezetimibe—atherosclerosis	0.000667	0.00806	CcSEcCtD
Pseudoephedrine—Asthenia—Rosuvastatin—atherosclerosis	0.000662	0.008	CcSEcCtD
Pseudoephedrine—Insomnia—Simvastatin—atherosclerosis	0.000662	0.008	CcSEcCtD
Pseudoephedrine—Pain—Ezetimibe—atherosclerosis	0.000656	0.00793	CcSEcCtD
Pseudoephedrine—Tachycardia—Niacin—atherosclerosis	0.000655	0.00792	CcSEcCtD
Pseudoephedrine—Dyspnoea—Simvastatin—atherosclerosis	0.000652	0.00788	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Niacin—atherosclerosis	0.000649	0.00785	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Lovastatin—atherosclerosis	0.000644	0.00779	CcSEcCtD
Pseudoephedrine—Dyspepsia—Simvastatin—atherosclerosis	0.000644	0.00778	CcSEcCtD
Pseudoephedrine—Anorexia—Niacin—atherosclerosis	0.00064	0.00774	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Pravastatin—atherosclerosis	0.000639	0.00773	CcSEcCtD
Pseudoephedrine—Decreased appetite—Simvastatin—atherosclerosis	0.000636	0.00769	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Ezetimibe—atherosclerosis	0.000632	0.00764	CcSEcCtD
Pseudoephedrine—Anorexia—Pravastatin—atherosclerosis	0.00063	0.00762	CcSEcCtD
Pseudoephedrine—Pain—Simvastatin—atherosclerosis	0.000625	0.00756	CcSEcCtD
Pseudoephedrine—Body temperature increased—Lovastatin—atherosclerosis	0.000618	0.00747	CcSEcCtD
Pseudoephedrine—Dizziness—Rosuvastatin—atherosclerosis	0.00061	0.00738	CcSEcCtD
Pseudoephedrine—Insomnia—Niacin—atherosclerosis	0.000607	0.00734	CcSEcCtD
Pseudoephedrine—Body temperature increased—Ezetimibe—atherosclerosis	0.000606	0.00733	CcSEcCtD
Pseudoephedrine—ADRA1A—adipose tissue—atherosclerosis	0.000605	0.0164	CbGeAlD
Pseudoephedrine—Feeling abnormal—Simvastatin—atherosclerosis	0.000603	0.00729	CcSEcCtD
Pseudoephedrine—MAOA—adipose tissue—atherosclerosis	0.0006	0.0162	CbGeAlD
Pseudoephedrine—ADRA2A—connective tissue—atherosclerosis	0.0006	0.0162	CbGeAlD
Pseudoephedrine—Dyspnoea—Niacin—atherosclerosis	0.000599	0.00724	CcSEcCtD
Pseudoephedrine—Insomnia—Pravastatin—atherosclerosis	0.000598	0.00723	CcSEcCtD
Pseudoephedrine—Dyspepsia—Niacin—atherosclerosis	0.000591	0.00715	CcSEcCtD
Pseudoephedrine—Dyspnoea—Pravastatin—atherosclerosis	0.00059	0.00713	CcSEcCtD
Pseudoephedrine—Decreased appetite—Niacin—atherosclerosis	0.000584	0.00706	CcSEcCtD
Pseudoephedrine—Dyspepsia—Pravastatin—atherosclerosis	0.000582	0.00704	CcSEcCtD
Pseudoephedrine—Rash—Rosuvastatin—atherosclerosis	0.000582	0.00703	CcSEcCtD
Pseudoephedrine—Dermatitis—Rosuvastatin—atherosclerosis	0.000581	0.00703	CcSEcCtD
Pseudoephedrine—Body temperature increased—Simvastatin—atherosclerosis	0.000578	0.00699	CcSEcCtD
Pseudoephedrine—Headache—Rosuvastatin—atherosclerosis	0.000578	0.00699	CcSEcCtD
Pseudoephedrine—Decreased appetite—Pravastatin—atherosclerosis	0.000575	0.00695	CcSEcCtD
Pseudoephedrine—Pain—Niacin—atherosclerosis	0.000574	0.00694	CcSEcCtD
Pseudoephedrine—Pain—Pravastatin—atherosclerosis	0.000565	0.00684	CcSEcCtD
Pseudoephedrine—Asthenia—Lovastatin—atherosclerosis	0.000561	0.00678	CcSEcCtD
Pseudoephedrine—Asthenia—Ezetimibe—atherosclerosis	0.00055	0.00665	CcSEcCtD
Pseudoephedrine—Nausea—Rosuvastatin—atherosclerosis	0.000548	0.00663	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Pravastatin—atherosclerosis	0.000545	0.00659	CcSEcCtD
Pseudoephedrine—Body temperature increased—Niacin—atherosclerosis	0.000531	0.00642	CcSEcCtD
Pseudoephedrine—Asthenia—Simvastatin—atherosclerosis	0.000525	0.00634	CcSEcCtD
Pseudoephedrine—Body temperature increased—Pravastatin—atherosclerosis	0.000523	0.00632	CcSEcCtD
Pseudoephedrine—Dizziness—Lovastatin—atherosclerosis	0.000517	0.00625	CcSEcCtD
Pseudoephedrine—Dizziness—Ezetimibe—atherosclerosis	0.000507	0.00613	CcSEcCtD
Pseudoephedrine—Vomiting—Lovastatin—atherosclerosis	0.000497	0.00601	CcSEcCtD
Pseudoephedrine—Rash—Lovastatin—atherosclerosis	0.000493	0.00596	CcSEcCtD
Pseudoephedrine—Dermatitis—Lovastatin—atherosclerosis	0.000493	0.00595	CcSEcCtD
Pseudoephedrine—Headache—Lovastatin—atherosclerosis	0.00049	0.00592	CcSEcCtD
Pseudoephedrine—Vomiting—Ezetimibe—atherosclerosis	0.000488	0.0059	CcSEcCtD
Pseudoephedrine—Dizziness—Simvastatin—atherosclerosis	0.000484	0.00585	CcSEcCtD
Pseudoephedrine—Rash—Ezetimibe—atherosclerosis	0.000484	0.00585	CcSEcCtD
Pseudoephedrine—Dermatitis—Ezetimibe—atherosclerosis	0.000483	0.00584	CcSEcCtD
Pseudoephedrine—Asthenia—Niacin—atherosclerosis	0.000482	0.00583	CcSEcCtD
Pseudoephedrine—Headache—Ezetimibe—atherosclerosis	0.00048	0.00581	CcSEcCtD
Pseudoephedrine—Asthenia—Pravastatin—atherosclerosis	0.000474	0.00574	CcSEcCtD
Pseudoephedrine—Vomiting—Simvastatin—atherosclerosis	0.000465	0.00562	CcSEcCtD
Pseudoephedrine—Nausea—Lovastatin—atherosclerosis	0.000464	0.00562	CcSEcCtD
Pseudoephedrine—Rash—Simvastatin—atherosclerosis	0.000461	0.00558	CcSEcCtD
Pseudoephedrine—Dermatitis—Simvastatin—atherosclerosis	0.000461	0.00557	CcSEcCtD
Pseudoephedrine—ADRA2A—adipose tissue—atherosclerosis	0.00046	0.0124	CbGeAlD
Pseudoephedrine—Headache—Simvastatin—atherosclerosis	0.000458	0.00554	CcSEcCtD
Pseudoephedrine—Nausea—Ezetimibe—atherosclerosis	0.000456	0.00551	CcSEcCtD
Pseudoephedrine—Dizziness—Niacin—atherosclerosis	0.000444	0.00537	CcSEcCtD
Pseudoephedrine—Dizziness—Pravastatin—atherosclerosis	0.000437	0.00529	CcSEcCtD
Pseudoephedrine—Nausea—Simvastatin—atherosclerosis	0.000434	0.00525	CcSEcCtD
Pseudoephedrine—Vomiting—Niacin—atherosclerosis	0.000427	0.00516	CcSEcCtD
Pseudoephedrine—ADRA1A—liver—atherosclerosis	0.000424	0.0115	CbGeAlD
Pseudoephedrine—Rash—Niacin—atherosclerosis	0.000423	0.00512	CcSEcCtD
Pseudoephedrine—Dermatitis—Niacin—atherosclerosis	0.000423	0.00511	CcSEcCtD
Pseudoephedrine—Headache—Niacin—atherosclerosis	0.000421	0.00509	CcSEcCtD
Pseudoephedrine—MAOA—liver—atherosclerosis	0.000421	0.0114	CbGeAlD
Pseudoephedrine—Vomiting—Pravastatin—atherosclerosis	0.00042	0.00508	CcSEcCtD
Pseudoephedrine—Rash—Pravastatin—atherosclerosis	0.000417	0.00504	CcSEcCtD
Pseudoephedrine—Dermatitis—Pravastatin—atherosclerosis	0.000417	0.00504	CcSEcCtD
Pseudoephedrine—Headache—Pravastatin—atherosclerosis	0.000414	0.00501	CcSEcCtD
Pseudoephedrine—Nausea—Niacin—atherosclerosis	0.000399	0.00482	CcSEcCtD
Pseudoephedrine—Nausea—Pravastatin—atherosclerosis	0.000393	0.00475	CcSEcCtD
Pseudoephedrine—CYP2D6—liver—atherosclerosis	0.00025	0.00676	CbGeAlD
Pseudoephedrine—ADRA2A—Metabolism—ABCA1—atherosclerosis	1.05e-05	4.39e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—PIK3CG—atherosclerosis	1.04e-05	4.37e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—NCF1—atherosclerosis	1.04e-05	4.36e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—APOE—atherosclerosis	1.03e-05	4.32e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PLAT—atherosclerosis	1.03e-05	4.32e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—GHRL—atherosclerosis	1.03e-05	4.32e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PARP1—atherosclerosis	1.03e-05	4.32e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—SOCS3—atherosclerosis	1.02e-05	4.3e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—CAV1—atherosclerosis	1.02e-05	4.28e-05	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—IL6—atherosclerosis	1.02e-05	4.28e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PLA2G1B—atherosclerosis	1.02e-05	4.27e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—APOA1—atherosclerosis	1.02e-05	4.27e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—F2—atherosclerosis	1.01e-05	4.25e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—SOCS3—atherosclerosis	1e-05	4.21e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—AGT—atherosclerosis	9.94e-06	4.17e-05	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—AKT1—atherosclerosis	9.93e-06	4.17e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MMP3—atherosclerosis	9.9e-06	4.15e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—F2—atherosclerosis	9.89e-06	4.15e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—IGF2—atherosclerosis	9.85e-06	4.13e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—ALOX5—atherosclerosis	9.84e-06	4.13e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CCR2—atherosclerosis	9.82e-06	4.12e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—EDNRA—atherosclerosis	9.82e-06	4.12e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CYBA—atherosclerosis	9.77e-06	4.1e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—PIK3CG—atherosclerosis	9.68e-06	4.06e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MMP3—atherosclerosis	9.68e-06	4.06e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—IGF2—atherosclerosis	9.64e-06	4.04e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PLAT—atherosclerosis	9.57e-06	4.01e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—GHRL—atherosclerosis	9.57e-06	4.01e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PARP1—atherosclerosis	9.57e-06	4.01e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—APOB—atherosclerosis	9.56e-06	4.01e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR downstream signaling—CXCL8—atherosclerosis	9.48e-06	3.98e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—PIK3CG—atherosclerosis	9.46e-06	3.97e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—EDN1—atherosclerosis	9.41e-06	3.95e-05	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—AKT1—atherosclerosis	9.4e-06	3.94e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—APOB—atherosclerosis	9.36e-06	3.93e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CCL5—atherosclerosis	9.34e-06	3.92e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—PIK3CG—atherosclerosis	9.3e-06	3.9e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—CXCL8—atherosclerosis	9.28e-06	3.89e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—EDN1—atherosclerosis	9.21e-06	3.86e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—F2—atherosclerosis	9.19e-06	3.86e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—VEGFA—atherosclerosis	9.16e-06	3.84e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CCL5—atherosclerosis	9.14e-06	3.83e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—LPL—atherosclerosis	9.13e-06	3.83e-05	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—IL6—atherosclerosis	9.11e-06	3.82e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—KNG1—atherosclerosis	9.04e-06	3.79e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—AGTR1—atherosclerosis	8.98e-06	3.77e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—HMOX1—atherosclerosis	8.98e-06	3.77e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—PPARG—atherosclerosis	8.97e-06	3.77e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—LPL—atherosclerosis	8.93e-06	3.75e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PRKCG—atherosclerosis	8.88e-06	3.73e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—NAMPT—atherosclerosis	8.82e-06	3.7e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—CCL2—atherosclerosis	8.81e-06	3.7e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—INS—atherosclerosis	8.8e-06	3.69e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—PIK3CG—atherosclerosis	8.79e-06	3.69e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—LIPC—atherosclerosis	8.77e-06	3.68e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PLG—atherosclerosis	8.75e-06	3.67e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—APOC3—atherosclerosis	8.71e-06	3.66e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PRKCG—atherosclerosis	8.69e-06	3.65e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—MAPK3—atherosclerosis	8.67e-06	3.64e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—LDLR—atherosclerosis	8.66e-06	3.63e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—SPP1—atherosclerosis	8.65e-06	3.63e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—CXCL8—atherosclerosis	8.61e-06	3.61e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—APOB—atherosclerosis	8.6e-06	3.61e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—SPP1—atherosclerosis	8.46e-06	3.55e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—CETP—atherosclerosis	8.46e-06	3.55e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—CXCL8—atherosclerosis	8.42e-06	3.53e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—TGFB1—atherosclerosis	8.41e-06	3.53e-05	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—AKT1—atherosclerosis	8.4e-06	3.53e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—KNG1—atherosclerosis	8.4e-06	3.52e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—GSTM1—atherosclerosis	8.37e-06	3.51e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—AGTR1—atherosclerosis	8.35e-06	3.5e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—SOCS3—atherosclerosis	8.29e-06	3.48e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—LPL—atherosclerosis	8.21e-06	3.45e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—CCL2—atherosclerosis	8.19e-06	3.44e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PLG—atherosclerosis	8.13e-06	3.41e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—SCARB1—atherosclerosis	8.1e-06	3.4e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—ALB—atherosclerosis	8.07e-06	3.39e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—GPX1—atherosclerosis	8.01e-06	3.36e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MMP3—atherosclerosis	8.01e-06	3.36e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PDGFB—atherosclerosis	8e-06	3.36e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—IGF2—atherosclerosis	7.97e-06	3.35e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PDGFB—atherosclerosis	7.83e-06	3.29e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—AGT—atherosclerosis	7.81e-06	3.28e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—CD36—atherosclerosis	7.8e-06	3.27e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—APOB—atherosclerosis	7.74e-06	3.25e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—NOS3—atherosclerosis	7.72e-06	3.24e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—SOCS3—atherosclerosis	7.7e-06	3.23e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—CXCL8—atherosclerosis	7.67e-06	3.22e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—APOE—atherosclerosis	7.66e-06	3.21e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—LEP—atherosclerosis	7.66e-06	3.21e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—HMGCR—atherosclerosis	7.65e-06	3.21e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—AGT—atherosclerosis	7.64e-06	3.21e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—EDN1—atherosclerosis	7.62e-06	3.2e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CAV1—atherosclerosis	7.58e-06	3.18e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—APOA1—atherosclerosis	7.57e-06	3.18e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CCL5—atherosclerosis	7.56e-06	3.17e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—LEP—atherosclerosis	7.49e-06	3.14e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—APOE—atherosclerosis	7.49e-06	3.14e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MMP3—atherosclerosis	7.44e-06	3.12e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CAV1—atherosclerosis	7.42e-06	3.11e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—IGF2—atherosclerosis	7.41e-06	3.11e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—APOA1—atherosclerosis	7.4e-06	3.11e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—MTHFR—atherosclerosis	7.39e-06	3.1e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—LPL—atherosclerosis	7.39e-06	3.1e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—ESR1—atherosclerosis	7.31e-06	3.07e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PPARA—atherosclerosis	7.25e-06	3.04e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—F2—atherosclerosis	7.22e-06	3.03e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—APOB—atherosclerosis	7.19e-06	3.02e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PRKCG—atherosclerosis	7.18e-06	3.01e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—ESR1—atherosclerosis	7.15e-06	3e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—CXCL8—atherosclerosis	7.13e-06	2.99e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—EDN1—atherosclerosis	7.08e-06	2.97e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—F2—atherosclerosis	7.06e-06	2.96e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—PTGS2—atherosclerosis	7.06e-06	2.96e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—AGT—atherosclerosis	7.02e-06	2.95e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CCL5—atherosclerosis	7.02e-06	2.95e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—SPP1—atherosclerosis	7e-06	2.94e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—CXCL8—atherosclerosis	6.97e-06	2.92e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PIK3CG—atherosclerosis	6.91e-06	2.9e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—APOE—atherosclerosis	6.88e-06	2.89e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—LPL—atherosclerosis	6.87e-06	2.88e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—CAV1—atherosclerosis	6.82e-06	2.86e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—ABCA1—atherosclerosis	6.82e-06	2.86e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—APOA1—atherosclerosis	6.8e-06	2.86e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PIK3CG—atherosclerosis	6.76e-06	2.84e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PRKCG—atherosclerosis	6.68e-06	2.8e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—MAPK3—atherosclerosis	6.62e-06	2.78e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—INS—atherosclerosis	6.54e-06	2.74e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—SPP1—atherosclerosis	6.5e-06	2.73e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PDGFB—atherosclerosis	6.48e-06	2.72e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—CXCL8—atherosclerosis	6.47e-06	2.72e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—MAPK3—atherosclerosis	6.47e-06	2.72e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CCL2—atherosclerosis	6.43e-06	2.7e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—INS—atherosclerosis	6.4e-06	2.68e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—IGF1—atherosclerosis	6.33e-06	2.65e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—AGT—atherosclerosis	6.32e-06	2.65e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CCL2—atherosclerosis	6.29e-06	2.64e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PIK3CG—atherosclerosis	6.21e-06	2.61e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—LEP—atherosclerosis	6.19e-06	2.6e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—APOE—atherosclerosis	6.19e-06	2.6e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—IGF1—atherosclerosis	6.19e-06	2.6e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CAV1—atherosclerosis	6.14e-06	2.58e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—APOA1—atherosclerosis	6.12e-06	2.57e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PDGFB—atherosclerosis	6.02e-06	2.52e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—SERPINE1—atherosclerosis	6.01e-06	2.52e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PPARG—atherosclerosis	5.99e-06	2.52e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—ESR1—atherosclerosis	5.91e-06	2.48e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—INS—atherosclerosis	5.88e-06	2.47e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—SERPINE1—atherosclerosis	5.88e-06	2.47e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—AGT—atherosclerosis	5.87e-06	2.46e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—HMOX1—atherosclerosis	5.85e-06	2.45e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—AKT1—atherosclerosis	5.85e-06	2.45e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—F2—atherosclerosis	5.84e-06	2.45e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—APOE—atherosclerosis	5.75e-06	2.41e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—LEP—atherosclerosis	5.75e-06	2.41e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—NOS3—atherosclerosis	5.73e-06	2.41e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CAV1—atherosclerosis	5.7e-06	2.39e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—APOA1—atherosclerosis	5.69e-06	2.39e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—NOS3—atherosclerosis	5.61e-06	2.35e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—APOB—atherosclerosis	5.6e-06	2.35e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PIK3CG—atherosclerosis	5.59e-06	2.35e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—ESR1—atherosclerosis	5.49e-06	2.31e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—GSTM1—atherosclerosis	5.45e-06	2.29e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—F2—atherosclerosis	5.43e-06	2.28e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—ALB—atherosclerosis	5.39e-06	2.26e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—MAPK3—atherosclerosis	5.35e-06	2.25e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—LPL—atherosclerosis	5.35e-06	2.25e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—INS—atherosclerosis	5.29e-06	2.22e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—GPX1—atherosclerosis	5.22e-06	2.19e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CCL2—atherosclerosis	5.21e-06	2.18e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PIK3CG—atherosclerosis	5.19e-06	2.18e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—NOS3—atherosclerosis	5.16e-06	2.16e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—IGF1—atherosclerosis	5.12e-06	2.15e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CXCL8—atherosclerosis	5.09e-06	2.13e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—CD36—atherosclerosis	5.08e-06	2.13e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CXCL8—atherosclerosis	4.98e-06	2.09e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	4.97e-06	2.09e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—INS—atherosclerosis	4.92e-06	2.06e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR downstream signaling—AKT1—atherosclerosis	4.91e-06	2.06e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—SERPINE1—atherosclerosis	4.86e-06	2.04e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—IL6—atherosclerosis	4.84e-06	2.03e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	4.84e-06	2.03e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—MTHFR—atherosclerosis	4.82e-06	2.02e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—AKT1—atherosclerosis	4.81e-06	2.02e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	4.76e-06	2e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—IL6—atherosclerosis	4.73e-06	1.99e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PPARA—atherosclerosis	4.73e-06	1.98e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PTGS2—atherosclerosis	4.72e-06	1.98e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—NOS3—atherosclerosis	4.64e-06	1.95e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MMP9—atherosclerosis	4.6e-06	1.93e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—AGT—atherosclerosis	4.58e-06	1.92e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—NFKB1—atherosclerosis	4.55e-06	1.91e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	4.52e-06	1.9e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MMP9—atherosclerosis	4.5e-06	1.89e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—APOE—atherosclerosis	4.48e-06	1.88e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MAPK8—atherosclerosis	4.47e-06	1.88e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—AKT1—atherosclerosis	4.46e-06	1.87e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—NFKB1—atherosclerosis	4.45e-06	1.87e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—CAV1—atherosclerosis	4.44e-06	1.86e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—APOA1—atherosclerosis	4.43e-06	1.86e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MAPK8—atherosclerosis	4.38e-06	1.84e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—AKT1—atherosclerosis	4.37e-06	1.83e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	4.31e-06	1.81e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—VEGFA—atherosclerosis	4.13e-06	1.73e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CXCL8—atherosclerosis	4.12e-06	1.73e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—STAT3—atherosclerosis	4.09e-06	1.72e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PIK3CG—atherosclerosis	4.05e-06	1.7e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—VEGFA—atherosclerosis	4.04e-06	1.7e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—STAT3—atherosclerosis	4e-06	1.68e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—AKT1—atherosclerosis	3.98e-06	1.67e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—IL6—atherosclerosis	3.91e-06	1.64e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—MAPK3—atherosclerosis	3.91e-06	1.64e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PPARG—atherosclerosis	3.91e-06	1.64e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—INS—atherosclerosis	3.83e-06	1.61e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	3.82e-06	1.6e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—MAPK3—atherosclerosis	3.82e-06	1.6e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—TGFB1—atherosclerosis	3.79e-06	1.59e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MMP9—atherosclerosis	3.72e-06	1.56e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—TGFB1—atherosclerosis	3.71e-06	1.56e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	3.69e-06	1.55e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—NFKB1—atherosclerosis	3.68e-06	1.55e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	3.64e-06	1.53e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MAPK8—atherosclerosis	3.62e-06	1.52e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—AKT1—atherosclerosis	3.61e-06	1.52e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—AKT1—atherosclerosis	3.55e-06	1.49e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—ALB—atherosclerosis	3.51e-06	1.47e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	3.46e-06	1.45e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	3.42e-06	1.44e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	3.36e-06	1.41e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—NOS3—atherosclerosis	3.36e-06	1.41e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	3.35e-06	1.41e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—VEGFA—atherosclerosis	3.34e-06	1.4e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—STAT3—atherosclerosis	3.31e-06	1.39e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—MAPK3—atherosclerosis	3.16e-06	1.33e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	3.11e-06	1.3e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	3.08e-06	1.29e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PTGS2—atherosclerosis	3.07e-06	1.29e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—TGFB1—atherosclerosis	3.07e-06	1.29e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	2.94e-06	1.23e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—IL6—atherosclerosis	2.86e-06	1.2e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	2.85e-06	1.2e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—IL6—atherosclerosis	2.8e-06	1.17e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—AKT1—atherosclerosis	2.64e-06	1.11e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—AKT1—atherosclerosis	2.58e-06	1.08e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—AKT1—atherosclerosis	2.37e-06	9.95e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—IL6—atherosclerosis	2.31e-06	9.7e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—IL6—atherosclerosis	2.15e-06	9.01e-06	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—AKT1—atherosclerosis	2.13e-06	8.95e-06	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	1.98e-06	8.32e-06	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—AKT1—atherosclerosis	1.54e-06	6.48e-06	CbGpPWpGaD
